Free Trial

Onconetix (ONCO) Competitors

Onconetix logo
$3.00 -0.15 (-4.76%)
Closing price 09/18/2025 04:00 PM Eastern
Extended Trading
$3.02 +0.02 (+0.67%)
As of 09/18/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ONCO vs. EDSA, CLRB, MTVA, IBIO, IXHL, NRSN, THAR, AIMD, LPCN, and BLRX

Should you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Edesa Biotech (EDSA), Cellectar Biosciences (CLRB), MetaVia (MTVA), iBio (IBIO), Incannex Healthcare (IXHL), NeuroSense Therapeutics (NRSN), Tharimmune (THAR), Ainos (AIMD), Lipocine (LPCN), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry.

Onconetix vs. Its Competitors

Edesa Biotech (NASDAQ:EDSA) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Edesa Biotech has a net margin of 0.00% compared to Onconetix's net margin of -3,327.03%. Edesa Biotech's return on equity of -162.95% beat Onconetix's return on equity.

Company Net Margins Return on Equity Return on Assets
Edesa BiotechN/A -162.95% -60.33%
Onconetix -3,327.03%-192.74%-89.55%

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 22.6% of Edesa Biotech shares are owned by insiders. Comparatively, 3.1% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Edesa Biotech currently has a consensus price target of $5.00, suggesting a potential upside of 117.39%. Given Edesa Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Edesa Biotech is more favorable than Onconetix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edesa Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Onconetix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Edesa Biotech's average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company Overall Sentiment
Edesa Biotech Neutral
Onconetix Neutral

Edesa Biotech has higher earnings, but lower revenue than Onconetix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edesa BiotechN/AN/A-$6.17M-$1.32-1.74
Onconetix$2.52M1.85-$58.69MN/AN/A

Edesa Biotech has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.36, indicating that its stock price is 236% more volatile than the S&P 500.

Summary

Edesa Biotech beats Onconetix on 8 of the 11 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCO vs. The Competition

MetricOnconetixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.88M$3.12B$5.78B$10.28B
Dividend YieldN/A2.37%5.74%4.64%
P/E RatioN/A21.3676.9426.98
Price / Sales1.85475.60543.88128.54
Price / CashN/A45.3237.1760.63
Price / Book0.279.6913.836.37
Net Income-$58.69M-$52.92M$3.29B$271.46M
7 Day Performance-1.64%2.19%1.57%2.53%
1 Month Performance8.30%8.96%6.87%9.42%
1 Year Performance-99.24%10.84%81.59%30.16%

Onconetix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCO
Onconetix
0.3573 of 5 stars
$3.00
-4.8%
N/A-99.3%$4.88M$2.52M0.0012
EDSA
Edesa Biotech
1.2785 of 5 stars
$2.41
-0.4%
$5.00
+107.5%
-45.5%$16.97MN/A-1.8320
CLRB
Cellectar Biosciences
3.396 of 5 stars
$5.29
+5.2%
$375.00
+6,988.8%
-91.3%$16.88MN/A-0.2710Short Interest ↓
MTVA
MetaVia
2.2234 of 5 stars
$0.68
-1.8%
$7.50
+1,006.2%
N/A$16.41MN/A0.008News Coverage
IBIO
iBio
1.691 of 5 stars
$0.83
-2.6%
$5.00
+500.4%
-51.1%$16.37M$375K-0.48100
IXHL
Incannex Healthcare
0.087 of 5 stars
$0.55
-6.3%
N/A-70.7%$16.05M$10K-0.453Gap Down
NRSN
NeuroSense Therapeutics
2.435 of 5 stars
$1.17
+0.9%
$14.00
+1,096.6%
-10.4%$15.99MN/A-2.1710
THAR
Tharimmune
2.3044 of 5 stars
$2.79
-5.7%
$17.00
+509.3%
-9.5%$15.88MN/A-0.462Gap Up
AIMD
Ainos
1.0386 of 5 stars
$3.38
-6.4%
N/A+45.3%$15.75M$20K-0.6840News Coverage
LPCN
Lipocine
2.6617 of 5 stars
$2.88
-1.0%
$9.00
+212.5%
-43.9%$15.61M$4.21M-3.3110Gap Up
BLRX
BioLineRx
2.6939 of 5 stars
$3.61
-0.8%
$26.00
+620.2%
-84.4%$15.38M$28.94M-0.4140

Related Companies and Tools


This page (NASDAQ:ONCO) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners